GlassScriptPhysician profile
Alfred Samura
NPI 1316470958
$6,587.86
in general payments reported to CMS, 2019-2025
21 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $216 · 2021: $639 · 2022: $507 · 2023: $1,600 · 2024: $3,413 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,272 · Food and Beverage: $1,881 · Education: $73.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,271.51 |
| Food and Beverage | $1,880.84 |
| Education | $73.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,359.07 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $1,251.58 | 2022-2024 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Boston Scientific Corporation | $1,247.42 | 2023 | Watchman Access System |
| Bard Peripheral Vascular, INC. | $885.39 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $543.60 | 2020-2024 | Lifevest |
| Atricure, INC. | $251.39 | 2022 | |
| Abbott Laboratories | $231.20 | 2021-2024 | Mitraclip |
| Janssen Pharmaceuticals, INC | $209.17 | 2020-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $116.87 | 2021 | |
| Haemonetics Corporation | $101.56 | 2023 | |
| Zoll Circulation INC | $80.37 | 2025 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Pfizer INC. | $72.98 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.72 | 2025 | Jardiance |
| Amgen INC. | $49.19 | 2023-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $28.04 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $26.07 | 2023 | Impella |
| Kowa Pharmaceuticals America, INC. | $20.39 | 2024 | Livalo |
| Scpharmaceuticals INC. | $16.72 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $14.66 | 2021 | |
| Merck Sharp & Dohme LLC | $14.44 | 2023 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $14.03 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Samura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.